NR4A2 and Parkinson disease: If the druggability, sex-dependency, and neuroprotective roles of NR4A2 or other candidate targets can be further substantiated, this could pave the way for subsequent preclinical investigations of adjuvant pharmacological strategies to reduce or alleviate sex-dependent molecular pathology in PD.